GI Dynamics expands reach of EndoBarrier in AU
12 May, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has revealed that two more Australian sites are offering its obesity and diabetes device therapy EndoBarrier and has published research into the treatment's mechanism of action.
dorsaVi's new CFO to lay foundation for growth
08 May, 2014 by Dylan Bushell-EmblingJerome Whelan has joined Melbourne-based motion analysis device developer dorsaVi as CFO to help the company set the stage for its international expansion.
Employee share schemes need repair in Budget
08 May, 2014As the Federal Budget looms, AusBiotech and Employee Ownership Australia and New Zealand are urging the government to remove impediments to Australian innovation by returning Employee Share Scheme (ESS) provisions to the pre-2009 position.
pSivida implant provides sustained antibody release
08 May, 2014 by Dylan Bushell-EmblingpSivida (ASX:PVA) has announced the findings of preclinical research showing that its Tethadur implant can provide long-term sustained release of Avastin and other antibody treatments.
Clinuvel recruiting for phase II vitiligo trial
06 May, 2014 by Dylan Bushell-EmblingClinuvel (ASX:CUV) has been cleared to commence recruiting for a phase II trial of Scenesse - a subdermal implant for treating melanin-based skin disorders - in vitiligo.
Express your interest in Medtech Industry Development Workshop
06 May, 2014The Australian Government is pleased to partner with industry to assist small businesses navigate Australian regulation and commercial growth pathways and invite expressions of interest in attending this free limited course in Melbourne on 26 May or Sydney on 2 June 2014.
Commission of Audit recommends cuts for industry, research and education
06 May, 2014 by Susan WilliamsonSome of the key recommendations in the recently released National Commission of Audit would remove support for the biotech and life sciences sector.
Novogen forms child cancer R&D partnership
05 May, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has entered separate research collaborations aimed at adapting its super-benzopyran drugs to treat solid childhood cancers and neurodegenerative diseases.
GI Dynamics raises $34.3m for EndoBarrier trial
05 May, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has raised $34.3m through a placement round to help fund its US phase II trial and other commercialisation efforts for EndoBarrier, its obesity and type 2 diabetes treatment.
QRxPharma replaces CEO after MoxDuo setback
02 May, 2014 by Dylan Bushell-EmblingQRxPharma's (ASX:QRX) long-serving CEO Dr John Holday has stepped down and been replaced by COO Dr Edward Rudnic, following its latest regulatory setback for dual-opioid drug Moxduo.
Fibrotech bought by Shire for at least $81m
02 May, 2014 by Dylan Bushell-EmblingMelbourne-based biopharma Fibrotech has agreed to be bought out by Shire for an initial US$75 million ($80.9 million). The deal will also involve development and regulatory milestone payments.
CardioCel calcification-free after six years: Admedus
01 May, 2014 by Dylan Bushell-EmblingThe six-year follow-up for the first patient enrolled in a phase II trial of Admedus's CardioCel tissue patch has detected no calcification issues or complications.
Mesoblast seeks FDA fast-track for GVHD treatment
01 May, 2014 by Dylan Bushell-EmblingMesoblast (ASX:MSB) will soon meet with the US FDA to discuss ways to accelerate the approval process for Prochymal, a stem cell-based treatment bought from Osiris Therapeutics, in GVHD.
STA to distribute Iluvien in A/NZ
29 April, 2014 by Dylan Bushell-EmblingSpecialised Therapeutics Australia has become the exclusive distributor in ANZ for Iluvien, a DMO treatment being commercialised by Alimera Sciences under licence from pSivida (ASX:PVA).
BioBusiness Asia Conference calls for presenting proposals
29 April, 2014The 2014 BioBusiness Asia Conference, this year combined with BioTaiwan Exhibition 2014 to enlarge the partnering candidate pool, is calling for proposals from companies interested in presenting.
